Enliven Therapeutics holder plans 15K share sale

Helen Collins, a shareholder of Enliven Therapeutics, plans to sell up to 15,000 shares of common stock through Jefferies LLC, with an aggregate market value of $762,900.00.

Rhea-AI Filing Summary

Helen Collins, a shareholder of Enliven Therapeutics, plans to sell up to 15,000 shares of common stock through Jefferies LLC, with an aggregate market value of $762,900.00. These 15,000 shares were acquired via stock options on 08/09/2022. Enliven Therapeutics had 71,000,000 common shares outstanding as of 07/17/2026; this is a baseline figure, not the amount being sold. Over the past three months, Collins sold 5,000 shares for $198,863.90 on 05/18/2026 and another 5,000 shares for $218,908.88 on 07/17/2026.

Key Figures

Planned shares to be sold: 15,000 shares Aggregate market value of planned sale: $762,900.00 Shares outstanding: 71,000,000 shares +3 more

6 metrics

Planned shares to be sold 15,000 shares Common stock to be sold through Jefferies LLC

Aggregate market value of planned sale $762,900.00 Total market value of 15,000 shares

Shares outstanding 71,000,000 shares Common shares outstanding as of 07/17/2026

Sale on 05/18/2026 5,000 shares for $198,863.90 Shares sold by Helen Collins during past 3 months

Sale on 07/17/2026 5,000 shares for $218,908.88 Shares sold by Helen Collins during past 3 months

Option-derived shares 15,000 shares Shares acquired via stock options on 08/09/2022

Key Terms

Stock Options, Securities To Be Sold, Securities Sold During The Past 3 Months

3 terms

Stock Options financial

"Common | 08/09/2022 | Stock Options | Enliven Therapeutics Inc."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Securities To Be Sold regulatory

"144: Securities To Be Sold"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share sale is disclosed for Enliven Therapeutics (ELVN)?

Shareholder Helen Collins plans to sell up to 15,000 Enliven Therapeutics common shares through Jefferies LLC. The planned sale has an aggregate market value of $762,900.00, based on the figures provided in the disclosure.

How many Enliven Therapeutics (ELVN) shares did Helen Collins sell recently?

Helen Collins sold 10,000 ELVN shares over the past three months. She sold 5,000 shares for $198,863.90 on 05/18/2026 and another 5,000 shares for $218,908.88 on 07/17/2026.

What is the aggregate market value of the proposed ELVN share sale?

The proposed sale of 15,000 Enliven Therapeutics shares has an aggregate market value of $762,900.00. This figure reflects the total market value associated with the shares that may be sold through Jefferies LLC.

How many Enliven Therapeutics (ELVN) shares are outstanding?

Enliven Therapeutics had 71,000,000 common shares outstanding as of 07/17/2026. This number provides context for the company’s total equity base and is separate from the 15,000 shares referenced in the planned sale.

How did Helen Collins acquire the Enliven Therapeutics (ELVN) shares she may sell?

The 15,000 Enliven Therapeutics shares identified for potential sale were acquired through stock options. The acquisition date listed for these option-derived shares is 08/09/2022, according to the disclosure details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 04:36 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001701247
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 Lookout Road, First Floor Boulder COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Collins Helen Louise
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave, 4th FL New York NY 10022	15000	762900.00	71000000	07/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/09/2022	Stock Options	Enliven Therapeutics Inc.			15000	08/09/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Helen Collins 6200 Lookout Road, First Floor Boulder CO 80301	Enliven Therapeutics, Inc.	05/18/2026	5000	198863.90
Helen Collins 6200 Lookout Road, First Floor Boulder CO 80301	Enliven Therapeutics, Inc.	07/17/2026	5000	218908.88

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 10/19/2025, and all representations regarding material non-public information were made as of the adoption of the plan.
Date of Notice	07/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	10/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Helen Collins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)